Human Milk Oligosaccharides Market Size, Share & Trends Analysis Report By Application (Infant Formula, Dietary Supplements, Functional Food and Beverage) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Human Milk Oligosaccharides Market Size

The global human milk oligosaccharides market size was valued at USD 304.53 million in 2025 and is projected to grow from USD 364.83 million in 2026 to USD 1547.89 million by 2034, registering a CAGR of 19.8% during the forecast period from 2026 to 2034. Asia Pacific dominated the human milk oligosaccharides market with a market share of 36.4% in 2025.

Infants' health, development, and protection are essential during the first few months of life. The natural and best method of feeding a baby is breastfeeding, which has a good impact on their development and health. Breast milk contains a wide variety of bioactive substances, including immunoglobulins, hormones, oligosaccharides, and others, and offers the newborn the perfect nutritional balance. After lactose and lipids, human milk's third most prevalent solid component, human milk oligosaccharides (HMOs), is a very significant and intriguing component. They are a collection of complex, indigestible sugars that are both structurally and physiologically varied.

Human milk oligosaccharides (HMOs), multipurpose glycans that are naturally present in human milk, are a significant component. They are particularly fascinating because of their abundance and variety in structural design. Human milk contains complex carbohydrates called human milk oligosaccharides (HMOs). They provide no nutritional purpose but are the third largest solid substance in breast milk after fat and lactose. The numerous health advantages of HMOs are what drive the industry. The infant gut microbiome is shaped early in life by HMOs' combined prebiotic, antimicrobial, and antiadhesive effects. This lowers the risk of acute illnesses and non-communicable diseases like asthma and allergies.

Application Insights

The infant formula section will most likely expand at a CAGR of 19.30% and hold the most significant revenue during the forecast period. Due to the linked health advantages of ingesting HMOs, the market saw a substantial demand for the use of HMOs in infant formula. HMOs, improve immunity by reducing the risk of infection through interactions with bacteria, viruses, or protozoa. This has led to a rise in the usage of HMOs in infant formula on a commercial scale. The critical factors in the infant formula market, which are increasingly global player investments in research & development activities for high product innovation on a large scale for the commercial production of HMOs, may contribute to some health benefits for infants by assisting them in developing a healthy microbiota linked to human breast milk.

In particular, for infant formulas, the FDA and EU ingredient regulatory bodies have established regulations for product approval of HMOs that ensure the safety of the ingredients and encourage manufacturers to use them. The market's major players are implementing strategic measures to increase their presence and capture significant market shares to meet the demand that is only expected to grow. During the forecast period, these factors are anticipated to fuel market expansion.

The dietary supplements section will hold the second-largest share while growing at the highest CAGR. The functional advantages of these products have increased demand for the biosynthetic synthesis of HMOs, which are used as additions in infant formula and dietary supplements. The availability of new technologies, such as enzymatic trans-glycosylation, which is used to artificially synthesize HMOs, is one of the key reasons and market trends that propel the human milk oligosaccharides' growth (HMO) market.

Due to their scarcity, HMOs were just recently used in dietary supplements, making it challenging to conduct biological effects studies. They are now available in quantities and at affordable costs for commercial purposes, including nutritional supplements, due to the switch from chemical synthesis to biotechnological manufacture. HMOs are used in dietary supplements for advantages like immune support, defense against bacterial and viral infections, comfort for the digestive system, and support for cognitive function.

Request Customizationto receive a tailored report.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The Asia Pacific is likely to command the milk oligosaccharides regional market while growing at a CAGR of 20.6%. Scientific research has shown that the HMOs found in human breast milk are difficult to digest, which gave rise to HMOs that are now manufactured commercially. Among the significant factors influencing the market is the rising consumer knowledge of the advantages of HMO in baby nutrition in the nation.

Key market participants are concentrating on increasing their footprint to attain significant economies of scale in response to the growing demand. To create a cutting-edge infant formula specifically for the Chinese market, Jennewein Biotechnologie teamed up with Yili Group, one of Asia's leading dairy producers. To create a product specifically suited for Chinese infants, the firms intend to combine Jennewein Biotechnologie's expertise in human milk oligosaccharides and Yili's expertise in the composition of Chinese breast milk.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Human Milk Oligosaccharides Market Trend

Europe will likely have a shareholding of USD 240 million, advancing at a CAGR of 18.72%. The United Kingdom is a prime revenue generator of the region. The industry's investments are bridging the gap between infant formula and human breast milk by producing oligosaccharides from human milk.

According to the Public Health England data from 2017, one in three HIV-positive adults are women, and these women cannot nurse their children. For such moms, HMO products are beneficial in ensuring that their infants receive the proper nutrients. The first infant milk to incorporate HMOs was introduced by SMA Nutrition, one of the leading food and nutrition research networks with research and development facilities in the United Kingdom. With the addition of 2'FL and LNnT, this formula contains gut flora almost identical to that of a breastfed infant.

The demand for HMO products has increased due to increased awareness of and research into its benefits. According to studies, a formula containing these HMOs promotes healthy development and helps a newborn's gut flora become more comparable to that of breastfed newborns.

Consumers' perspectives on health and well-being have radically shifted in the UK. The demand for foods with functional properties, such as those that boost immunity and reduce stress, has increased. HMOs and associated functional foods are essential to give the necessary nutrients and immunity. HMOs, serve a crucial role in protecting immunity and sustaining nourishment. The regional milk oligosaccharides market is predicted to develop due to this tendency.

List of Key and Emerging Players in Human Milk Oligosaccharides Market